GPN — Global Payments Inc.

Sentiment is genuinely split rather than bearish. The bull case has momentum: shares are +30.4% over three months and +28.6% over six, the analyst panel is net positive (37 buys, 22 holds, 4 sells; consensus target $99.43 versus $88.29 spot, high $125, low $80), Wolfe Research upgraded to Outperform, RBC lifted its target to $106, and 13F filings showed Legal & General and CPPIB adding. The bear case is equally concrete: the August 5, 2026 Q2 print came with a trimmed FY2026 outlook (4-5% constant-currency revenue growth, EPS $13.60-$13.80) because Middle East conflict suppressed high-margin cross-border travel volume, and the shares gave back 4.59% in the week into 2026-09-13. RSI of 47.63 and a price ~11-13% below the average target capture that ambivalence - the market likes the capital-return plan but does not trust the forward numbers yet.

The reported series is not organically comparable, and reading it straight will mislead. Revenue ran ~$2.43-2.48B per quarter through 2023 and ~$1.97-2.52B in 2024, then fell to ~$1.90-2.41B across 2025 (asset divestitures), before jumping to $2.97B in Q1 2026 and $3.32B in Q2 2026 - a +69.7% YoY leap - as a major acquisition consolidated: total assets went from $53.3B (2025-12-31) to $64.3B (2026-03-31) and long-term debt from $19.5B to $21.0B, with stockholders' equity rising even through a $1.80B quarterly loss, which is the signature of a share-funded deal closing. Margins have compressed hard on the new mix and purchase accounting: gross margin fell from 72.3% in Q3 2025 to 61.0% in Q2 2026, operating margin from 31.8% to 10.2%, and Q1 2026 net income was -$1.80B (-$7.49/share), dragging TTM GAAP EPS to -$3.69. Organic growth guidance is only 4-5% constant currency and was cut, not raised. Cash is the softest spot: FY2025 free cash flow of $2.04B was already below FY2024's $2.86B, and H1 2026 FCF was negative (-$123M) with TTM FCF of $823M. Verdict: a discontinuous, M&A-driven revenue step-up paired with real margin and cash-conversion deterioration - an inflection in scale, not yet in quality.

Cheap, but the cheapness comes with strings. As of 2026-09-13 the TTM P/E of -22.6 and net margin of -9.4% are artifacts of the Q1 2026 GAAP loss, not operating reality. The numbers that matter: 6.47x forward earnings ($88.29 / $13.645 next-FY EPS estimate), PEG of 0.167, P/B of 0.991 (a payments company trading at book), P/S of 2.15 versus a 3.27x five-year average, and EV/EBITDA of 13.06 on GAAP EBITDA that falls to roughly 7x on the post-deal adjusted EBITDA the guidance implies. The deterministic model also flags it 'Cheap vs. its own history' (96.4/100). The discount to the payments peer set (roughly 10-12x forward) is real but partly earned - 4-5% organic growth, ~$16.1B net debt, beta 0.785, and negative H1 2026 free cash flow are not qualities that command a full multiple. My read: undervalued on adjusted earnings and cash-return capacity, fairly-to-fully valued if H1 2026 cash conversion proves structural.

At $88.29 the market pays 6.5x the $13.60-$13.80 FY2026 adjusted EPS guidance, versus roughly 11x forward earnings for GPN in the pre-Worldpay era - about 40-45% of the multiple has been removed. You are being paid to disbelieve one of two things: that H2 2026 delivers the ~$6.75+ of EPS still needed to hit guidance after $3.46 in Q2, or that adjusted EPS converts to cash, given TTM free cash flow of $823M against a negative GAAP bottom line. The consensus target of $99.43 (recent average $97.44, high $125, low $80) implies only ~13% upside - even the sell side is not extrapolating a re-rating. If the November 3, 2026 print shows cross-border recovery and positive free cash flow, an 8-9x multiple on ~$13.65 is the base case and the stock is materially cheap; if cash conversion stays negative, the low multiple is a trap rather than a discount. Trade the print, not the narrative.

As of 2026-09-13 the stock sat at $88.29 with RSI(14) of 47.63 - dead neutral, neither oversold nor overbought. It was 3.43% below its 20-day SMA (~$91.4) but 2.74% above its 50-day (~$85.9) and 16.19% above its 200-day (~$76.0), with three-month return of +30.4% and six-month of +28.6% confirming a strong intermediate uptrend that is now consolidating. The one-week -4.59% and one-month -0.27% say near-term momentum has stalled just under the 20-day and below the $95.88 52-week high. Practical implication: this reads as a healthy pullback inside an uptrend rather than a breakdown, but RSI at 47.6 provides no urgency to chase. Better entry zones are a 50-day retest near ~$86 or a 200-day retest near ~$76; buying a 20-day reclaim without a fundamental catalyst offers poor reward-for-risk.

• Rates: the 10-year Treasury near or above 4.7% caps fintech valuation multiples and raises refinancing costs on GPN's $21.5B of long-term debt (~$16.1B net of $5.4B cash), a direct earnings drag for a leveraged balance sheet.
• Geopolitics: Middle East conflict is directly suppressing high-margin cross-border and travel-adjacent transaction volume - the explicit reason for the August 5, 2026 FY2026 guidance cut to 4-5% constant-currency growth.
• Consumer spending: GPN's transaction-fee revenue is levered to retail and travel card volume; any consumer slowdown hits Merchant Solutions volume growth immediately, with no pricing offset.
• Regulation: ongoing global scrutiny of interchange fees and digital wallet interoperability remains a sector-wide multiple overhang, partly offset by the pivot toward integrated software and embedded payments.
• Competitive structure: vertical software and integrated POS (Stripe, Adyen, Block, Toast, Fiserv/Clover) keep compressing take rates and are the main driver of scale-driven consolidation like Worldpay - a structural reason GPN's multiple may not fully revert.

• Q3 2026 earnings on November 3, 2026 (consensus ~$3.58 EPS): the key tell on cross-border/travel recovery, Worldpay cost synergies, and whether free cash flow turns positive in H2.
• Evidence of H2 2026 free-cash-flow normalization to support the $2B+ annual capital-return plan - on a $21.9B market cap, that is roughly 9% of shares per year, a powerful EPS tailwind if funded from cash rather than debt.
• Continued Worldpay integration and the new three-segment operating framework; any upward revision to the $13.60-$13.80 EPS guide would be the first positive revision in a while and likely force a re-rating.
• Analyst re-rating and institutional accumulation: Wolfe upgraded to Outperform and RBC moved to $106 post-Q2; more upgrades plus 13F adds (Legal & General, CPPIB) can close the gap to the $99.43 consensus target.
• Portfolio simplification or divestiture announcements and accelerated deleveraging following the close of the transformational deal.

• Cash conversion: H1 2026 free cash flow was -$123M and TTM FCF is $823M against roughly $3.4B of implied adjusted net income - if that gap is structural rather than integration timing, the 1.13% dividend and the buyback are effectively debt-funded.
• Leverage and refinancing: $21.5B long-term debt, ~$16.1B net debt, roughly 3x adjusted EBITDA, a current ratio of 0.825, and refinancing into a ~4.7% 10-year Treasury.
• Guidance risk: FY2026 growth was already cut to 4-5% constant currency on Middle East travel weakness; a second cut would undermine the 10%+ EPS algorithm that the capital-return story depends on.
• Integration and impairment risk: the Worldpay-scale deal closed in Q1 2026, and the $1.80B GAAP loss in that quarter shows goodwill/impairment charges are a live possibility if synergy targets slip.
• Competitive disintermediation: merchant software platforms and bank in-sourcing pressure both Merchant Solutions and Issuer Solutions, and the on-GAAP economics are weak - operating margin 11.9%, net margin -9.4%, ROIC 2.5%, ROE 6.1%.

GPN is a show-me value situation, not a clean compounder. At 6.5x forward adjusted EPS, 0.99x book, 2.15x sales versus a 3.27x five-year average, a 1.13% dividend yield, and $2B+ of annual capital return against a $21.9B market cap, a lot of skepticism is already priced in - if H2 2026 cash conversion normalizes and cross-border volumes recover, the multiple has room toward 8-9x and the stock is worth well over $100. The offset is real: 4-5% organic growth, ~$16.1B of net debt, and negative H1 2026 free cash flow mean the discount is defensible until the November 3, 2026 print proves otherwise. Own it for re-rating optionality with the FCF/guidance thesis as the stop, not as a core growth holding.

Blend of three anchors as of 2026-09-13: (a) 8.0x FY2026E adjusted EPS of $13.645 = $109, a ~25-30% discount to the ~11x payments peer/pre-Worldpay multiple GPN used to carry, justified by 4-5% organic growth and ~$16.1B net debt; (b) 2.5x P/S on $41.07 of TTM sales per share ($88.29 / 2.15), still below the 3.27x five-year average = $103; and (c) a 10% required FCF yield on ~$2.3B of mid-cycle normalized free cash flow (between FY2025's $2.04B and a post-Worldpay run-rate) = ~$93. Weighted 50/30/20, that produces ~$104, about 18% above the $88.29 spot price and modestly above the $99.43 sell-side consensus target.